Brief: Ascletis Announces Ind Approval Of Oral Viral Polymerase Inhibitor Asc10 For Monkeypox Indication By China Nmpa
26/01/2023 13:23
Jan 26 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES IND APPROVAL OF ORAL VIRAL POLYMERASE
INHIBITOR ASC10 FOR MONKEYPOX INDICATION BY CHINA NMPA
* ASCLETIS PHARMA- RECEIVED NOTICE OF ISSUANCE FROM USPTO
FOR
PATENT APPLICATION OF ASC10 & DERIVATIVES & THEIR USES TO TREAT
MULTIPLE VIRUS INFECTIONS
Source text for Eikon: ID:nPnfDl0la
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management